![]() | Dave SinghUniversity of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. | Medicines Evaluation Unit, University of Manchester, Manchester University National ... |
KOL Resume for Dave Singh
Year | |
---|---|
2022 | University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. Medicines Evaluation Unit and. |
2021 | Medicines Evaluation Unit, University of Manchester, Manchester, UK From the Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Respiratory Sciences, University of Leicester, Leicester (C.E.B., D.J.C.), and the University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) - both in the United Kingdom; the Firestone Institute for Respiratory Health, McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada (P.N.); and the GIGA-I3 Research Unit, University of Liege, Department of Pneumology, Centre Hospitalier Universitaire Liège, Liege, Belgium (R.L.). |
2019 | Centre for Respiratory Medicine and Allergy, The University of Manchester, Manchester, UK |
2017 | University of Manchester, Medicines Evaluation Unit and University Hospital of South Manchester Foundation Trust, Manchester, United Kingdom |
2016 | Centre for Respiratory Medicine and Allergy, The University of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK |
2015 | The University of Manchester, Centre for Respiratory and Allergy, Manchester Academic Health and Science Centre, University Hospital of South Manchester Foundation Trust, Manchester, UK. |
2012 | For author affiliations, see the Acknowledgements section |
2009 | U.S. Army RDECOM-ARDEC Advanced Energy Armament Systems Center, Bldg. 65N, Picatinny Arsenal, New Jersey, 07806, USA |
2008 | Medicines Evaluation Unit, The Langley Building, University Hospital of South Manchester NHS Trust, University of Manchester, Southmoor Road, Manchester M23 9QZ, UK. |
2006 | North West Lung Research Centre, South Manchester University Hospitals Trust Manchester, UK M23 9LT |
2000 | Center for Perinatal Biology, Loma Linda University Medical Center, Loma Linda, California 92350 |
Dave Singh: Influence Statistics
Concept | World rank |
---|---|
fine triple | #6 |
inhaled syk | #6 |
airway diseasedominant | #13 |
standardisation qct indices | #13 |
terms laboratory testing | #13 |
standardisation qct | #13 |
standardised qct | #13 |
qct indices emphysema | #13 |
qct indices | #15 |
inhaled nebulised ufh | #16 |
scanner conformity | #18 |
nebulised interferon | #22 |
trimaran trigger | #23 |
lower gas transfer | #25 |
inhaled nebulised | #25 |
airway wall geometry | #26 |
nebulised unfractionated | #26 |
extrafine triple therapy | #26 |
dna streptococcus tomography | #27 |
community composition lungs | #27 |
specific microbiome structures | #27 |
nebulised ufh | #28 |
patients severe subtypes | #29 |
disease delineate | #29 |
ubiopred copd | #34 |
brushings copd | #34 |
eva asthma | #34 |
noneosinophilic copd cases | #34 |
bronchial brushings copd | #34 |
copd eva | #34 |
count biopred | #34 |
airway disease copd | #35 |
suffering defined | #35 |
disease eva | #36 |
emphysemadominant | #36 |
young patients copd | #37 |
copd young patients | #37 |
prevotella pulmonary | #42 |
lung define | #42 |
young patients time | #43 |
copd biology | #44 |
transcriptome relationships | #44 |
streptococcus severe | #46 |
eosinophilic asthma copd | #48 |
eosinophilic versus | #48 |
meta trial | #49 |
indices emphysema | #49 |
dominant copd | #49 |
designated mild | #50 |
plethysmography impulse | #50 |
Open the FULL List in Excel | |
Prominent publications by Dave Singh
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study
[ PUBLICATION ]
BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma.
METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with ...
Known for Small Airways Dysfunction | Asthma Control | Impulse Oscillometry | Prospective Cohort Study | Physiological Tests |
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries a substantial risk of severe and prolonged illness; treatment options are currently limited. We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19.
METHODS: We did a randomised, double-blind, placebo-controlled, phase 2 pilot trial at nine UK sites. Adults aged 18 years or older and admitted to hospital ...
Known for Patients Placebo | Nebulised Interferon | Sarscov2 Infection | Odds Ratio 95 | Covid19 Symptoms |
Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma
[ PUBLICATION ]
BACKGROUND: Whether the clinical or pathophysiologic significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma.
METHODS: Subjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of ...
Known for Blood Eosinophil | Asthma Copd | Gene Expression | Airway Disease | Lung Function |
Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography
[ PUBLICATION ]
EvA (Emphysema versus Airway disease) is a multicentre project to study mechanisms and identify biomarkers of emphysema and airway disease in chronic obstructive pulmonary disease (COPD). The objective of this study was to delineate objectively imaging-based emphysema-dominant and airway disease-dominant phenotypes using quantitative computed tomography (QCT) indices, standardised with a novel phantom-based approach.441 subjects with COPD (Global Initiative for Chronic Obstructive Lung ...
Known for Computed Tomography | Airway Disease | Copd Phenotypes | Pulmonary Emphysema | Chronic Obstructive |
Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome
[ PUBLICATION ]
BACKGROUND: Changes in microbial community composition in the lung of patients suffering from moderate to severe COPD have been well documented. However, knowledge about specific microbiome structures in the human lung associated with CT defined abnormalities is limited.
METHODS: Bacterial community composition derived from brush samples from lungs of 16 patients suffering from different CT defined subtypes of COPD and 9 healthy subjects was analyzed using a cultivation independent ...
Known for Pulmonary Disease | Chronic Obstructive | Lung Microbiome | Bacterial Communities | Copd Patients |
The EvA study is a European Union-funded project under the Seventh Framework Programme (FP7), which aims at defining new markers for chronic obstructive pulmonary disease (COPD) and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes, are driven by different genes ...
Known for Airway Disease | Eva Study | Computed Tomography | Pulmonary Emphysema | Blood Samples |
BACKGROUND: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.
METHODS: We conducted a phase 2a, multicenter, randomized, double-blind, placebo-controlled, 24-week, parallel-group trial to assess the efficacy and safety of risankizumab, an anti-interleukin-23p19 monoclonal antibody, in adults with severe ...
Known for Severe Asthma | Controlled Trial | Airway Inflammation | 2 Type | Agents Antibodies |
AIMS: Inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID-19. UFH has antiviral effects and prevents the SARS-CoV-2 virus' entry into mammalian cells. In addition, UFH has significant anti-inflammatory and anticoagulant properties, which limit progression of lung injury and vascular pulmonary thrombosis.
METHODS: The INHALEd nebulised unfractionated HEParin ...
Known for Unfractionated Heparin | Hospitalised Patients | Randomised Studies | Mechanical Ventilation | Anticoagulant Properties |
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: "young" individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at ...
Known for Chronic Obstructive | Pulmonary Disease | Respiratory Symptoms | Environment Interactions | Copd Older |
Chronic Obstructive Pulmonary Disease, Neutrophils and Bacterial Infection: A Complex Web Involving IL-17 and IL-22 Unravels
[ PUBLICATION ]
Known for Chronic Obstructive | Pulmonary Disease | Bacterial Infection |
Reproductive, Neuroendocrine, and Immune Consequences of Acute Exposure to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in the Siberian Hamster1
[ PUBLICATION ]
The present study tested the hypothesis that acute treatment with 2, 3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) impairs fertility, disrupts the nocturnal melatonin rhythm, and suppresses lymphocyte function. Adult Siberian hamsters administered 2 or 100 microg TCDD/kg body weight/0.2 ml sesame oil had a delayed latency to first litter and an increased adult mortality compared to hamsters given 0.1 microg/kg or vehicle. Within 75 days of TCDD treatment, full reproductive capabilities were ...
Known for Circadian Rhythm | Dioxin Tcdd | 2378 Tetrachlorodibenzo | Time Day |
New insights into the optimal management of COPD: extracts from CHEST 2021 annual meeting (October 17-20, 2021).
[ PUBLICATION ]
INTRODUCTION: Discordance between real-world prescribing patterns and global treatment guidelines for the treatment of chronic obstructive pulmonary disease (COPD) with inhaled single or dual long-acting bronchodilator maintenance therapy is increasingly being reported in the literature, particularly with regard to addition of inhaled corticosteroids (ICS). Patient-related factors, e.g. inhalation technique and inspiratory flow, are key to disease control in COPD. Treatment discordance ...
Known for Pulmonary Disease | Chronic Obstructive |
Key People For Copd Patients
Dave Singh:Expert Impact
Concepts for whichDave Singhhas direct influence:Copd patients, Pulmonary disease, Obstructive pulmonary, Mild asthma, Hospitalised patients, Chronic obstructive, Severe asthma, Persistent asthma.
Dave Singh:KOL impact
Concepts related to the work of other authors for whichfor which Dave Singh has influence:Small airways, Severe asthma, Chronic obstructive, Pulmonary disease, Lung function, Copd patients, Sarscov2 infection.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |